<DOC>
	<DOCNO>NCT00003440</DOCNO>
	<brief_summary>This randomized phase III study well two different regimen paclitaxel without trastuzumab work treat patient without HER-2/Neu breast cancer inoperable , recurrent , metastatic . Drugs use chemotherapy , paclitaxel , use different way stop tumor cell divide stop grow die . Monoclonal antibody , trastuzumab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know regimen paclitaxel effective without trastuzumab treat patient breast cancer .</brief_summary>
	<brief_title>Paclitaxel With Without Trastuzumab Treating Patients With Without HER-2/Neu Breast Cancer That Inoperable , Recurrent , Metastatic</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether `` dose dense '' ( DD ) treatment paclitaxel via weekly 1-hour infusion significantly high response rate `` standard '' ( S ) paclitaxel treatment , regardless human epidermal growth factor receptor 2 ( HER-2/neu ) status assignment Herceptin ( trastuzumab ) . II . To determine addition Herceptin DD S paclitaxel significantly improve response rate compare DD S paclitaxel alone HER-2/neu non-overexpressing metastatic breast cancer ( e.g. , 0 1+ ) . III . To determine whether addition Herceptin chemotherapy treatment modifies quality life experienced patient HER-2/neu non-overexpressing metastatic breast cancer . IV . To determine whether quality life experience patient metastatic breast cancer treat `` standard '' paclitaxel treatment differ patient treat `` dose dense '' paclitaxel treatment . V. To correlate amplification overexpression growth factor receptor ErbB2 immunohistochemistry fluorescent in-situ hybridization ( FISH ) response rate , time progression , overall survival patient metastatic breast cancer treat paclitaxel chemotherapy paclitaxel + Herceptin . VI . To correlate ErbB2 shed extracellular domain ( ECD ) response rate , time progression , overall survival patient metastatic breast cancer treat different dos schedule paclitaxel paclitaxel + Herceptin . In addition , follow pattern ErbB2/ECD treatment upon relapse . SECONDARY OBJECTIVES : I . To evaluate time progression survival patient HER-2 overexpressing metastatic breast cancer treat either DD S paclitaxel plus weekly Herceptin . II . To evaluate time progression survival patient HER-2 non-overexpressing metastatic breast cancer treat either DD S paclitaxel alone DD S paclitaxel plus weekly Herceptin . III . To evaluate cardiac toxicity measure change LVEF baseline follow-up measurement . OUTLINE ; Patients assign 1 2 treatment group . GROUP I ( HER2/neu non-overexpressors ) : Patients randomize 1 4 treatment arm . ARM A : Patients receive paclitaxel intravenously ( IV ) 3 hour every 3 week . ARM B : Patients receive paclitaxel IV 1 hour weekly . ARM C : Patients receive paclitaxel Arm A . Patients also receive trastuzumab IV weekly . ARM D : Patients receive paclitaxel Arm B trastuzumab Arm C. GROUP II ( HER2/neu overexpression ) : Patients assign 1 2 treatment arm . ARM E : Patients receive paclitaxel trastuzumab Arm C. ARM F : Patients receive paclitaxel trastuzumab Arm D. In arm , course repeat every 3 week absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm adenocarcinoma female breast inoperable , recurrent metastatic HER2/neu status must know time protocol registration ; HER2/neu assessment base FISH analysis either primary tumor metastatic site ; score 0 1+ immunohistochemistry ( IHC ) consider negative ; 2+ consider negative unless confirm FISH positivity , case consider positive ; 3+ IHC consider positive ; center use FISH , positive FISH assay sufficient determine HER2 positivity Patients follow prior therapy eligible : Patients 01 prior chemotherapy regimens metastatic locally advanced breast cancer , follow exception : prior taxane metastatic/locally advance breast cancer Patients 01 prior chemotherapy regimen adjuvant setting ; adjuvant regimen include taxane , patient must disease free least 12 month completion adjuvant therapy relapse Patients must &gt; 2 week prior surgery , simple biopsy placement venous access device ; patient must &gt; 4 week prior chemotherapy ; patient must &gt; 6 week nitrosoureas , melphalan , mitomycin Patients must &gt; 4 week prior hormonal therapy unless tumor measurement document clear progression treatment ; progression document toxicity hormonal regimen resolve , patient may place study &gt; 1 week prior hormonal therapy Prior Herceptin therapy allow Patients central nervous system metastasis eligible patient complete cranial irradiation least 6 month prior , currently asymptomatic , currently receive corticosteroid condition ; patient leptomeningeal carcinoma ( carcinomatous meningitis ) eligible MESURABLE DISEASE : Any mass reproducibly measurable two perpendicular dimension , example include : Pulmonary nodule Hepatic lesion Skin nodule ( two measurement assign ) Lymph nod The following lesion qualify measurable : Central nervous system ( CNS ) lesions Bone disease ; lytic lesion document follow Lymphangitic pulmonary metastasis ( patient lymphangitic metastasis eligible site metastatic disease measure ) Lesions irradiate unless definite documentation progression since radiotherapy A baseline assessment leave ventricular ejection fraction within 8 week registration require ( echocardiogram resting multi gate acquisition scan [ MUGA ] ( radionuclide cineangiography [ RNCA ] ) nuclear scintigraphy ) ; patient leave ventricular ejection fraction ( LVEF ) &lt; 45 % ineligible Granulocytes &gt; = 1500/ul Platelet count &gt; = 100,000/ul Creatinine = &lt; 2.0 mg/dl Bilirubin within institutional normal limit Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>